Drugmaker GSK posts slumping Q1 profits

April 24, 2013

British drugs firm GlaxoSmithKline on Wednesday said its first-quarter net profit tumbled by almost a third, with the group hit by falling sales and a poor economic climate.

, which also has a large consumer healthcare division, confirmed that it planned to sell drinks brands Lucozade and Ribena as part of its European restructuring plans.

Profit after tax dived to £961 million ($1.47 billion, 1.12 billion euros) in the first quarter from £1.3 billion in the same part of 2012, the pharmaceuticals firm said in a results statement.

Pre-tax profit slid to £1.41 billion from £1.86 billion last time around.

Sales dropped three percent to £6.47 billion compared with the same period of last year, dented partly by the sale of GSK's non-core over-the-counter brands in 2012.

"The commercial environment in Europe remains challenging and unpredictable, and we continue to be cautious about the outlook here," chief executive Andrew Witty said in the statement.

He added that GSK had completed its strategic review into fruit-flavoured soft drink Ribena and energy drink Lucozade, which are both primarily established in Western markets.

"We... concluded that the tremendous growth potential of these iconic brands, particularly outside the core Western markets, could be better leveraged by companies with existing category presence and infrastructure in these regions," he said.

"As a result, we have decided to pursue the divestment of these brands, subject to the realisation of appropriate value for GSK shareholders."

Witty added that GSK was "on track" to deliver total annual savings of at least £1.0 billion by 2016, under a restructuring programme that was launched earlier this year.

GSK also ramped up its shareholder dividend by six percent to 18 pence per share.

However, 's share price fell 0.42 percent to 1,671.5 pence in late afternoon deals on London's FTSE 100 index of leading companies, which was 0.48 percent higher at 6,436.98 points.

Wednesday's result were published almost one week after GSK revealed that it had received a US recommendation for approval of its Breo Ellipta inhaler treatment for chronic obstructive pulmonary disease (COPD).

Explore further: Drugmaker GSK reveals lower profits, restructuring

Related Stories

Drugmaker GSK reveals lower profits, restructuring

February 6, 2013
British drugs firm GlaxoSmithKline on Wednesday unveiled a 13-percent drop in annual net profits and outlined a plan for more restructuring in Europe to deliver greater savings and offset weaker sales across the region.

GlaxoSmithKline says net profits drop 13% in Q1

April 25, 2012
British drugsmaker GlaxoSmithKline said Wednesday that its net profits dropped 13 percent to £1.325 billion (1.616 billion euros, $2.134 billion) in the first quarter from a year earlier.

GlaxoSmithKline says annual profits triple to £5.26 bln

February 7, 2012
British drugmaker GlaxoSmithKline said Tuesday that net profits more than tripled in 2011 compared with the previous year, as large efficiency savings offset falling revenues.

GlaxoSmithKline posts rising Q3 profits

October 26, 2011
British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profit rose seven percent, boosted by growth across its main pharmaceuticals, vaccines and consumer healthcare divisions.

GlaxoSmithKline profits up on lower tax

July 25, 2012
British drugmaker GlaxoSmithKline on Wednesday said its second quarter net profit rose 13.3 percent from a year earlier to £1.25 billion ($1.94 billion, 1.59 billion euros).

GlaxoSmithKline reports return to profit in second quarter

July 26, 2011
British drugmaker GlaxoSmithKline posted net profit of more than £1.1 billion in the second quarter on Tuesday following a loss during the equivalent three-month period in 2010.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.